NCT05651672View on ClinicalTrials.gov

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Gastrointestinal Cancer
Interventions
DRUG

Pemigatinib

13.5mg, po, 2 weeks on/1 week off, Q3W

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER